125 related articles for article (PubMed ID: 25707975)
1. Development of amino acid substituted gemini surfactant-based mucoadhesive gene delivery systems for potential use as noninvasive vaginal genetic vaccination.
Singh J; Michel D; Getson HM; Chitanda JM; Verrall RE; Badea I
Nanomedicine (Lond); 2015 Feb; 10(3):405-17. PubMed ID: 25707975
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cellular uptake and intracellular trafficking as determining factors of gene expression for amino acid-substituted gemini surfactant-based DNA nanoparticles.
Singh J; Michel D; Chitanda JM; Verrall RE; Badea I
J Nanobiotechnology; 2012 Feb; 10():7. PubMed ID: 22296763
[TBL] [Abstract][Full Text] [Related]
3. Amino acid-substituted gemini surfactant-based nanoparticles as safe and versatile gene delivery agents.
Singh J; Yang P; Michel D; Verrall RE; Foldvari M; Badea I
Curr Drug Deliv; 2011 May; 8(3):299-306. PubMed ID: 21291379
[TBL] [Abstract][Full Text] [Related]
4. In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes.
Badea I; Verrall R; Baca-Estrada M; Tikoo S; Rosenberg A; Kumar P; Foldvari M
J Gene Med; 2005 Sep; 7(9):1200-14. PubMed ID: 15895387
[TBL] [Abstract][Full Text] [Related]
5. Enhanced gene expression in epithelial cells transfected with amino acid-substituted gemini nanoparticles.
Yang P; Singh J; Wettig S; Foldvari M; Verrall RE; Badea I
Eur J Pharm Biopharm; 2010 Aug; 75(3):311-20. PubMed ID: 20417276
[TBL] [Abstract][Full Text] [Related]
6. Dicationic Amino Substituted Gemini Surfactants and their Nanoplexes: Improved Synthesis and Characterization of Transfection Efficiency and Corneal Penetration In Vitro.
Narsineni L; Foldvari M
Pharm Res; 2020 Jul; 37(7):144. PubMed ID: 32666411
[TBL] [Abstract][Full Text] [Related]
7. New serine-derived gemini surfactants as gene delivery systems.
Cardoso AM; Morais CM; Cruz AR; Silva SG; do Vale ML; Marques EF; de Lima MC; Jurado AS
Eur J Pharm Biopharm; 2015 Jan; 89():347-56. PubMed ID: 25513958
[TBL] [Abstract][Full Text] [Related]
8. Structural and transfection properties of amine-substituted gemini surfactant-based nanoparticles.
Wettig SD; Badea I; Donkuru M; Verrall RE; Foldvari M
J Gene Med; 2007 Aug; 9(8):649-58. PubMed ID: 17654656
[TBL] [Abstract][Full Text] [Related]
9. Cellular Uptake and Distribution of Gemini Surfactant Nanoparticles Used as Gene Delivery Agents.
Jin W; Al-Dulaymi M; Badea I; Leary SC; Rehman J; El-Aneed A
AAPS J; 2019 Aug; 21(5):98. PubMed ID: 31388860
[TBL] [Abstract][Full Text] [Related]
10. Di-Peptide-Modified Gemini Surfactants as Gene Delivery Vectors: Exploring the Role of the Alkyl Tail in Their Physicochemical Behavior and Biological Activity.
Al-Dulaymi MA; Chitanda JM; Mohammed-Saeid W; Araghi HY; Verrall RE; Grochulski P; Badea I
AAPS J; 2016 Sep; 18(5):1168-1181. PubMed ID: 27184577
[TBL] [Abstract][Full Text] [Related]
11. Peptide-Modified Gemini Surfactants: Preparation and Characterization for Gene Delivery.
Al-Dulaymi M; Mohammed-Saeid W; El-Aneed A; Badea I
Methods Mol Biol; 2019; 2000():203-225. PubMed ID: 31148017
[TBL] [Abstract][Full Text] [Related]
12. Bis-quaternary gemini surfactants as components of nonviral gene delivery systems: a comprehensive study from physicochemical properties to membrane interactions.
Cardoso AM; Morais CM; Silva SG; Marques EF; de Lima MC; Jurado MA
Int J Pharm; 2014 Oct; 474(1-2):57-69. PubMed ID: 25111434
[TBL] [Abstract][Full Text] [Related]
13. Development of long-acting bioadhesive vaginal gels of oxybutynin: formulation, in vitro and in vivo evaluations.
Tuğcu-Demiröz F; Acartürk F; Erdoğan D
Int J Pharm; 2013 Nov; 457(1):25-39. PubMed ID: 24036011
[TBL] [Abstract][Full Text] [Related]
14. Design and Evaluation of RGD-Modified Gemini Surfactant-Based Lipoplexes for Targeted Gene Therapy in Melanoma Model.
Mohammed-Saeid W; Chitanda J; Al-Dulaymi M; Verrall R; Badea I
Pharm Res; 2017 Sep; 34(9):1886-1896. PubMed ID: 28643235
[TBL] [Abstract][Full Text] [Related]
15. Interactions between DNA and Gemini surfactant: impact on gene therapy: part I.
Ahmed T; Kamel AO; Wettig SD
Nanomedicine (Lond); 2016 Feb; 11(3):289-306. PubMed ID: 26785905
[TBL] [Abstract][Full Text] [Related]
16. Advancing nonviral gene delivery: lipid- and surfactant-based nanoparticle design strategies.
Donkuru M; Badea I; Wettig S; Verrall R; Elsabahy M; Foldvari M
Nanomedicine (Lond); 2010 Sep; 5(7):1103-27. PubMed ID: 20874024
[TBL] [Abstract][Full Text] [Related]
17. Gemini surfactants mediate efficient mitochondrial gene delivery and expression.
Cardoso AM; Morais CM; Cruz AR; Cardoso AL; Silva SG; do Vale ML; Marques EF; Pedroso de Lima MC; Jurado AS
Mol Pharm; 2015 Mar; 12(3):716-30. PubMed ID: 25634573
[TBL] [Abstract][Full Text] [Related]
18. Molecular Engineering as an Approach To Modulate Gene Delivery Efficiency of Peptide-Modified Gemini Surfactants.
Al-Dulaymi M; Michel D; Chitanda JM; El-Aneed A; Verrall RE; Grochulski P; Badea I
Bioconjug Chem; 2018 Oct; 29(10):3293-3308. PubMed ID: 30169953
[TBL] [Abstract][Full Text] [Related]
19. Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice.
Badea I; Wettig S; Verrall R; Foldvari M
Eur J Pharm Biopharm; 2007 Mar; 65(3):414-22. PubMed ID: 17292593
[TBL] [Abstract][Full Text] [Related]
20. Mass Spectrometric Detection and Characterization of Metabolites of Gemini Surfactants Used as Gene Delivery Vectors.
Jin W; Purves R; Krol E; Badea I; El-Aneed A
J Am Soc Mass Spectrom; 2020 Feb; 31(2):366-378. PubMed ID: 31922726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
